(Q42288097)

19 October 2017

title

Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial (English)

1 reference

19 October 2017

1 reference

Yves Benhamou

1

1 reference

19 October 2017

Joseph Moussalli

2

1 reference

19 October 2017

Vlad Ratziu

3

1 reference

19 October 2017

Pascal Lebray

4

1 reference

19 October 2017

Katrien De Backer

5

1 reference

19 October 2017

Sandra De Meyer

6

1 reference

19 October 2017

Anne Ghys

7

1 reference

19 October 2017

Donghan Luo

8

1 reference

19 October 2017

Gaston R Picchio

9

1 reference

19 October 2017

Maria Beumont

10

1 reference

19 October 2017

language of work or name

English

0 references

publication date

24 June 2013

1 reference

Journal of Infectious Diseases

19 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

19 October 2017

volume

208

1 reference

19 October 2017

issue

6

1 reference

19 October 2017

page(s)

1000-1007

1 reference

Genetic diversity and evolution of hepatitis C virus--15 years on

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Molecular heterogeneity and new subtypes of HCV genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Hepatitis C genotype 4: What we know and what we don't yet know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Genetic epidemiology of hepatitis C virus throughout egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Telaprevir for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

The role of triple therapy in HCV genotype 1-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT274

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIT274

1 reference

19 October 2017

1 reference